The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket.

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements ...

The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...

Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer ...

The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of ...